International Psoriasis Council

Advancing Knowledge. Improving Care.

Wilson

Liao

,

MD

Professor and Associate Vice Chair of Research
University of California San Francisco
San Francisco
,
California
,
United States
Councilor Since: June 22, 2023
IPC Councilor
Dr. Wilson Liao is a Professor and Associate Vice Chair of Research in the UCSF Department of Dermatology. He serves as Director of the UCSF Psoriasis and Skin Treatment Center and is deeply engaged in patient care, clinical trials, and translational research. The Liao Laboratory studies the genetics, immunology, and environmental triggers of psoriasis, atopic dermatitis, and hidradenitis suppurativa and uses machine learning and precision medicine approaches to advance dermatologic care. Dr. Liao directs the UCSF Psoriasis Research Initiative and Biobank with over 1,500 subjects, contributing to discovering over 60 psoriasis genes. He serves as Co-Principal Investigator of the NIH Accelerating Medicines Project Psoriatic Disease Team, leveraging single-cell and spatial profiling technologies to identify the cellular drivers of psoriasis. He co-founded Trex Bio, a biotechnology company developing novel therapeutics for inflammatory skin disease, and Solay, a telehealth company offering in-home therapy for psoriasis and eczema. Dr. Liao is also engaged in digital health initiatives and has developed SkinTracker, a mobile app allowing remote dermatology trials.
Last Updated:
04/21/2026

Areas of Interest

Genetics, genomics, immunology, precision medicine, digital health, biologic therapy, comorbidities, sleep, and environmental triggers

IPC Committees / Groups

Fellowship Program Advisory Committee

Languages Spoken

English

Involvement with Other Organization(s)

National Psoriasis Foundation, Medical Board; National Psoriasis Foundation, Scientific Advisory Committee; Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), Co-Chair of Research Committee; Arthritis Foundation, Psoriatic Arthritis Expert Panel; Skin of Color Society, Member

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026